Highlights of the 10th International Congress on Behçet's disease

Clinical and Experimental Rheumatology

Volumn 20, Issue 4 SUPPL. 26, 2002, Pages

  Fresko, Izzet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR CCR2; CHOLERA TOXIN B SUBUNIT; CYCLOSPORIN; ETANERCEPT; HEAT SHOCK PROTEIN 60; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 8 RECEPTOR; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLELE; BEHCET DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SAFETY; GENETIC ANALYSIS; HAPLOTYPE; HUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; TH1 CELL; GENETICS; MEDICAL SOCIETY;

BEHCET SYNDROME; HUMANS; SOCIETIES, MEDICAL;

EID: 0036656558     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Prevalence of Behçet's disease among Iraqis
2. The change of clinical manifestations of patients with Behçet's disease in Japan
3. Recent epidemiological data on Behçet's disease in Iran, The 2001 survey
4. Current epidemiological data from the German registry of Adamantiades-Behçet's disease
5. Clinical and genetic characteristics of late onset Behçet's disease
6. Complex aphthosis: Evaluation for Behçet's disease?
7. Is long term observation of patients with recurrent apthous stomatitis necessary? Clinical follow up of 1238 cases
8. The effect of nicotine on the clinical features of Adamantiades-Behçet's disease
9. The effects of smoking on oral ulcers (OU) of Behçet's syndrome (BS)
10. UVB induced erythema in Behçet's disease
11. Prognostic factors, treatment and long term follow up of patients with parenchymal neuro-Behçet's disease
12. Risk factors of neuro-Behçet
13. Spinal cord involvement in neuro-Behçet's disease
14. Epileptic seizures in Behçet's disease
15. Neurological Behçet's disease (NBD): Evaluation of 109 patients
16. Characteristics of uveitis in Behçet's disease
17. Fluorescein angiography and optical coherence tomography in ocular Behçet's disease
18. Chronology of clinical manifestations in Behçet's disease, analysis of 3542 cases
19. The long term mortality and morbidity of Behçet's syndrome (BS)
20. Clinical manifestations and course of 200 Japanese patients with Behçet's disease
21. Influence of sex on patients with Behçet's disease in Korea
22. Univariate and multivariate analysis comparing demographic, genetic, clinical and serologic risk factors for severe Adamantiades-Behçet's disease
23. Malignancy in Behçet's disease: Report of thirteen cases and a review of the literature
24. The Behçet's disease activity index (BDAI)
25. Development of a clinical activity form for Korean patients with Behçet's disease
26. IBBDAM vs Leeds scoring to measure disease activity in Behçet's patients
27. Simultaneous application of the Leeds Behçet's Disease Activity Form and the Pincus Multidimensional Health Assessment Questionnaire in patients with Behçet's syndrome
28. Quality of life in Behçet's disease: A controlled study
29. Whole genome screening of multicase families with Behçet's disease
30. Chemokine gene polymorphisms and gender in UK patients with Behçet's disease
31. The TNF - 1031C polymorphism is associated with Behçet's disease in a UK cohort of patients
32. The ICAM1469*E susceptibility to ocular and thrombotic manifestations in Korean patients with Behçet's disease
33. Polymorphisms in the endothelial nitric oxide synthase gene associated with Behçet's disease
34. Sequencing of the ID4 and DEK genes in the novel linkage region for Behçet's disease in the telomere of chromosome 6p
35. Polymorphisms of CXCR-2 in Behçet's disease
36. Interleukin 8 gene polymorphisms in Behçet's disease
37. No association of NOD2 gene 3020C insertion mutation with Behçet's disease in Turkish patients
38. Strong association of MIC-A*009 of extracellular domains and MIC-A*A6 of transmembrane domain in Korean patients with Behçet's disease
39. MICA transmembrane region polymorphism and HLA B 51 in Tunisian Behçet's disease patients
40. Familial segregation analysis in Behçet's disease: Evidence for a Mendelian entity in the pediatric subgroup
41. HLA antigen, severity and acetylator phenotype in Behçet's disease patients with non-relative parents
42. MEFV mutations are increased in Behçet's disease and associate with vascular involvement
43. Lukocyte phenotype and cytokine expression at the skin pathergy reaction in Behçet's syndrome: Evidence for a Type I immune response
44. Immunophenotype and Th1/Th2 cytokines in patients with Adamantiades-Behçet's disease
45. In situ cytokine expression within mucocutaneous lesions of Behçet's disease
46. Both Th1 and Th2 cytokines are present in oral ulcers of Behçet's patients
47. Differential release of cytokines and chemokines in neuro-Behçet's disease
48. KIR and C-type Lectine receptor expression in Behçet's disease
49. Histologic and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet's disease
50. Histological polymorphism of vasculitis in Behçet's disease
51. Serum levels of soluble TNF receptor-II (p75), circulating gamma delta T cells and Adamantiades Behçet's disease activity
52. Soluble Fas-ligand levels in cerebrospinal fluid in neuro-Behçet's disease
53. Expression of BCL-2 in inflammatory sites from active Behçet's disease
54. A distinct serological marker for Behçet's disease-Anti-Saccharomyces cerevisiae antibodies
55. Abscence of antisaccharomyces cerevisiae antibodies (ASCA) in BD
56. Autoimmunity to S-antigen and retinal vasculitis in patients with Behçet's disease
57. T-gamma delta receptor restriction in peripheral lymphocytes in patients with Behçet's disease
58. Low serum mannose binding lectin levels in Behçet's disease
59. Comparison of proteome map between sera of patients with Behçet's disease and control
60. L-selectin expression on leucocytes of patients with Behçet's disease
61. Variables associated with vascular thrombosis in Behçet's disease
62. Does hyperhomocysteinemia increase the risk of thrombosis in Behçet's disease?
63. Role of thrombogenic factors in dural sinus thrombosis (DST) due to Behçet's disease: A study of 41 patients
64. Arterial wall characteristics in patients with Adamantiades-Behçet's disease
65. The role of procoagulant mutations on the type and site of thrombosis in Behçet's disease
66. Factor V Leiden mutation does not correlate with ocular occlusion in UK patients with Behçet's disease
67. Detection of microbial DNA in skin lesions from patients with Behçet's disease
68. Investigation of immunogenic proteins from Streptococcus sanguis in Behçet's disease
69. Antimicrobial activity of synthetic human CAP18 peptides to Streptococcus sanguis isolated from patients with Behçet's disease
70. Cytokine production from PBMC stimulated by Streptococcus sanguis antigen in patients with Behçet's disease
71. Cytokine responses to in vitro Streptococcus sanguis stimulation in Behçet's disease
72. Dental and periodontal health in Behçet's disease
73. Behçet's disease: Visual acuity after 5 years in patients with alpha-interferon treatment
74. Interferon-alpha for the treatment of Behçet's disease-review of the literature: Own experiences and possible mechanisms of action
75. Immunopathogenesis and prevention of uveitis with the BD-specific peptide linked to Cholera Toxin B
76. Phase I trail of oral tolerization with heat shock protein peptide linked to Cholera Toxin B subunit in the treatment of Behçet's disease
77. A double blind placebo controlled trial of etanercept on the mucocutaneous lesions of Behçet's syndrome
78. The response of treatment resistant uveitis in Behçet's syndrome to a TNF-α blocker etanercept: An open study
79. Infliximab in refractory panuveitis due to Behçet's disease
80. Effect of infliximab in the treatment of Behçet's disease unresponsive to standard therapy. Report of three cases
81. Infliximab in the treatment of refractory posterior uveitis associated with Behçet's syndrome
82. Effect anti-tumour necrosis factor (Infliximab) on sight threatening pan uveitis in a patient with Behçet's disease
83. Successful long-term treatment of refractory Adamantiades-Behçet's disease with infliximab: Report of two patients
84. Pentoxifylline use for mucocutaneous ulcerations in Behçet's patients: A survey of rheumatologists in the United States and Canada
85. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short term results on 23 patients